ArticleTherapeutic advances in drug safety2026
The FMB scale: a multifactorial metric to assess the driving hazard of medicines beyond the DRUID system.
Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Driving while undergoing pharmacological treatment poses a significant risk to road safety. The Driving under the Influence of Drugs, Alcohol, and Medicines (DRUID) system, currently used to classify medicines according to their impact on driving ability, has important limitations, including the absence of classification for numerous drugs, low reproducibility, and limited clinical applicability. Objectives: To develop a continuous, multifactorial metric capable of refining the estimation of medication-related driving risk and to assess its preliminary performance compared with the traditional DRUID system. Design: Methodological development and initial validation study. Methods: In this study, we propose a new multifactorial risk scale, validated by healthcare professionals and engineers, which integrates key pharmacological and clinical variables. The scale combines six weighted criteria: DRUID category, frequency and severity of adverse reactions, number of driving-related adverse reactions, marketed dose, treatment initiation versus chronic treatment, and pharmaceutical dosage form. Each variable was normalized to a 0-1 scale to ensure comparability. In addition, correction mechanisms were introduced to avoid bias arising from the presence of multiple adverse reactions with unknown frequencies, ensuring robustness to incomplete data. Results: When applied to different clinically used medicines, the scale showed greater sensitivity and accuracy in discriminating risk compared with the traditional DRUID system, reproducing its qualitative categorization while providing finer intraclass resolution, particularly for medicines situated near risk thresholds. Conclusion: This tool offers a more flexible, reproducible, and clinically applicable approach with the potential for integration into e-prescribing, mobile health applications, and community pharmacy support systems, supporting more nuanced and evidence-based clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.